NL-OMON48893招募中不适用
A retrospective and prospective longitudinal observational study to assess changes in working capacity related to disease specific factors in Huntington*s disease - Working capacity and burn out in Huntington's Disease (HD-work)
适应症
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 入组人数
- 170
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 18 至 99(—)
入选标准
- •All eligible participants must meet the following inclusion criteria:
- •- Have a confirmed CAG-expansion of *36 in the HTT gene.
- •- Be employed, or have been employed 2 years prior to assessment, in any capacity (e.g. full time (paid job for 36 hours or more), part-time (paid job for less than 36 hours) or volunteer (unpaid job)).
- •- Be at least 18 years of age.
- •- Be at most 64 years of age, due to the longitudinal set up of the research and the age of retirement in the Netherlands.
排除标准
- •All eligible participants must meet none of the following exclusion criteria:
- •- Major general or neurological comorbidity that is unrelated to HD.
- •- Any other condition that in the opinion of the investigator warrants exclusion of the study.
- •- Inability to understand the information about the study.
研究者
相似试验
已完成
不适用
REMIC TOXIN: Utility in REnal disease of Measuring Indoxyl sulphate and p-Cresyl sulphate To predict OXidative stress, Inflammation and cliNical outcomesRenal and Urogenital - Kidney diseaseCardiovascular - Coronary heart diseaseChronic Kidney DiseaseCardiovascular diseaseACTRN12612000760875Princess Alexandra Hospital300
进行中(未招募)
不适用
COVID-19 Vaccine effectiveness and hesitancy study in Healthcare Workers of Max Group of HospitalsCTRI/2021/01/030782CSIRInstitute of Genomics and Integrative Biology
进行中(未招募)
不适用
A Study with additional chart review to evaluate clinical and biochemical characteristics and disease progression in patients with mucopolysaccharidosis type IIIBMucopolysaccharidosis type IIIBE76.2RBR-3rx9fjHospital de Clínicas de Porto Alegre
进行中(未招募)
1 期
A study aiming to collect data and provide a better understanding of the long-term outcome of imlifidase in treatment of immunological graft rejection in kidney transplant patientsAntibody-mediated rejection in kidney transplant patientsMedDRA version: 20.0Level: PTClassification code 10023439Term: Kidney transplant rejectionSystem Organ Class: 10021428 - Immune system disordersEUCTR2020-004777-49-ATHansa Biopharma30
招募中
不适用
An Observational & analysis of use, advantages, disadvantages & significance of neuromonitoring in spine surgeries.CTRI/2021/04/032957Stavya Spine Hospital and Research Institute
